GlaxoSmithKline Pharmaceuticals shares fall 2.06% in today's trading session

Disclaimer This is an AI-assisted live blog with updates sourced from multiple news outlets and agencies Disclaimer

shares experienced a downturn, with the price falling by 2.06% to Rs 2819.60 during today's session. The decline positions it among the NIFTY MIDCAP 150 index.

The stock's movement has drawn attention, especially given the prevailing sentiment analysis from Moneycontrol, which was very bullish as of May 14, 2025.

Financial Overview

A review of GlaxoSmithKline Pharmaceuticals' financial performance reveals the following trends:

Revenue

The company's revenue has shown consistent growth over the past five years:

• Mar 2025: Rs 3,749.21 Cr
• Mar 2024: Rs 3,453.71 Cr
• Mar 2023: Rs 3,251.72 Cr
• Mar 2022: Rs 3,278.03 Cr
• Mar 2021: Rs 2,925.60 Cr

Net Profit

Net profit has also seen a notable increase:

• Mar 2025: Rs 927.58 Cr
• Mar 2024: Rs 589.96 Cr
• Mar 2023: Rs 607.64 Cr
• Mar 2022: Rs 380.77 Cr
• Mar 2021: Rs 287.27 Cr

Earnings Per Share (EPS)

The EPS figures reflect this upward trend:

• Mar 2025: Rs 54.52
• Mar 2024: Rs 41.14
• Mar 2023: Rs 36.08
• Mar 2022: Rs 99.29
• Mar 2021: Rs 31.35

Quarterly Performance

Analyzing the quarterly results, the revenue and net profit figures are as follows:

• Mar 2025: Revenue of Rs 974.37 Cr, Net Profit of Rs 262.87 Cr
• Dec 2024: Revenue of Rs 949.42 Cr, Net Profit of Rs 229.88 Cr
• Sep 2024: Revenue of Rs 1,010.77 Cr, Net Profit of Rs 252.50 Cr
• Jun 2024: Revenue of Rs 814.65 Cr, Net Profit of Rs 182.33 Cr
• Mar 2024: Revenue of Rs 929.80 Cr, Net Profit of Rs 194.48 Cr

Balance Sheet Highlights

Key balance sheet metrics provide further insight into the company's financial health:

• Share Capital: Stable at Rs 169 Cr from 2021 to 2025
• Reserves & Surplus: Increased from Rs 1,308 Cr in 2021 to Rs 1,781 Cr in 2025
• Total Assets: Grew from Rs 3,114 Cr in 2021 to Rs 4,108 Cr in 2025

Key Financial Ratios

Several financial ratios offer a deeper understanding of GlaxoSmithKline Pharmaceuticals' performance:

• Return on Equity (ROE): 47.53% in Mar 2025
• Debt to Equity: 0.00 throughout the period
• Basic EPS: Rs 54.52 in Mar 2025

Cash Flow

Cash flow from operating activities has been consistently positive:

• Mar 2025: Rs 1,289 Cr
• Mar 2024: Rs 582 Cr
• Mar 2023: Rs 484 Cr

With the stock's current price at Rs 2819.60, GlaxoSmithKline Pharmaceuticals is navigating through market dynamics, reflected by its inclusion in the NIFTY MIDCAP 150 index.